ST PharmLtd Past Earnings Performance
Past criteria checks 3/6
ST PharmLtd has been growing earnings at an average annual rate of 67.5%, while the Pharmaceuticals industry saw earnings growing at 11.5% annually. Revenues have been growing at an average rate of 26.8% per year. ST PharmLtd's return on equity is 4.6%, and it has net margins of 8%.
Key information
67.5%
Earnings growth rate
67.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 26.8% |
| Return on equity | 4.6% |
| Net Margin | 8.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Should You Be Adding ST PharmLtd (KOSDAQ:237690) To Your Watchlist Today?
Nov 22
ST Pharm Co.,Ltd.'s (KOSDAQ:237690) Shares Climb 29% But Its Business Is Yet to Catch Up
Aug 30Is Now The Time To Put ST PharmLtd (KOSDAQ:237690) On Your Watchlist?
Aug 17Is ST Pharm Co.,Ltd. (KOSDAQ:237690) Trading At A 41% Discount?
May 09Why ST PharmLtd's (KOSDAQ:237690) Earnings Are Better Than They Seem
Mar 22ST Pharm Co.,Ltd. (KOSDAQ:237690) Stock Rockets 54% As Investors Are Less Pessimistic Than Expected
Mar 18Investors Who Bought ST PharmLtd (KOSDAQ:237690) Shares A Year Ago Are Now Up 221%
Mar 16Calculating The Fair Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)
Jan 22What Type Of Shareholders Own The Most Number of ST Pharm Co.,Ltd. (KOSDAQ:237690) Shares?
Dec 23Health Check: How Prudently Does ST PharmLtd (KOSDAQ:237690) Use Debt?
Nov 26
Revenue & Expenses Breakdown
How ST PharmLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 272,887 | 21,706 | 40,943 | 24,108 |
| 31 Mar 24 | 286,069 | 22,027 | 41,582 | 25,984 |
| 31 Dec 23 | 284,992 | 19,581 | 41,308 | 30,450 |
| 30 Sep 23 | 264,760 | 11,544 | 42,264 | 32,170 |
| 30 Jun 23 | 269,638 | 17,810 | 42,274 | 31,163 |
| 31 Mar 23 | 262,987 | 19,882 | 39,767 | 29,660 |
| 31 Dec 22 | 249,322 | 18,000 | 37,665 | 26,306 |
| 30 Sep 22 | 200,659 | 10,981 | 34,932 | 22,933 |
| 30 Jun 22 | 186,130 | 8,285 | 32,361 | 23,176 |
| 31 Mar 22 | 175,363 | 10,241 | 29,902 | 20,930 |
| 31 Dec 21 | 165,642 | 3,312 | 27,895 | 18,218 |
| 30 Sep 21 | 161,689 | 3,841 | 23,271 | 16,984 |
| 30 Jun 21 | 137,778 | -10,640 | 21,705 | 13,790 |
| 31 Mar 21 | 131,198 | -13,064 | 20,772 | 13,011 |
| 31 Dec 20 | 124,109 | -12,147 | 19,510 | 13,204 |
| 30 Sep 20 | 115,724 | -17,794 | 18,765 | 16,999 |
| 30 Jun 20 | 113,385 | -11,788 | 15,596 | 16,856 |
| 31 Mar 20 | 97,736 | -17,366 | 12,310 | 16,158 |
| 31 Dec 19 | 93,257 | -18,529 | 9,036 | 15,060 |
| 30 Sep 19 | 74,084 | -17,228 | 8,434 | 10,242 |
| 30 Jun 19 | 67,420 | -22,920 | 8,531 | 10,030 |
| 31 Mar 19 | 85,107 | -15,330 | 8,439 | 9,250 |
| 31 Dec 18 | 97,738 | -9,268 | 9,097 | 8,773 |
| 30 Sep 18 | 132,399 | 6,823 | 8,543 | 9,279 |
| 30 Jun 18 | 162,380 | 21,376 | 7,966 | 9,237 |
| 31 Mar 18 | 183,300 | 32,346 | 7,742 | 9,368 |
| 31 Dec 17 | 202,800 | 44,997 | 7,879 | 9,663 |
| 30 Sep 17 | 193,639 | 48,990 | 7,186 | 8,979 |
| 30 Jun 17 | 204,253 | 57,391 | 7,143 | 8,689 |
| 31 Mar 17 | 217,291 | 65,196 | 7,207 | 8,757 |
| 31 Dec 16 | 200,362 | 61,426 | 6,475 | 8,582 |
| 30 Sep 16 | 198,740 | 58,742 | 6,065 | 8,830 |
| 30 Jun 16 | 190,495 | 54,579 | 5,575 | 9,468 |
| 31 Dec 15 | 138,052 | 25,189 | 6,204 | 10,342 |
Quality Earnings: A237690 has a large one-off loss of ₩8.1B impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: A237690's current net profit margins (8%) are higher than last year (6.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A237690 has become profitable over the past 5 years, growing earnings by 67.5% per year.
Accelerating Growth: A237690's earnings growth over the past year (21.9%) is below its 5-year average (67.5% per year).
Earnings vs Industry: A237690 earnings growth over the past year (21.9%) exceeded the Pharmaceuticals industry 21.6%.
Return on Equity
High ROE: A237690's Return on Equity (4.6%) is considered low.